Atlanta Genitourinary Cancers Summit - Enduring Recorded Webcast

Overview

This accredited continuing education activity “Atlanta Genitourinary Cancers Summit - Enduring Recorded Webcast ”, is recorded from the live conference held on 03/15/25. 

If you participated in the live conference titled - Atlanta Genitourinary Cancers Summit on 03/15/25 and claimed CME credits/MOC points for that activity, you do not qualify for CME credits/MOC points for your participation in this enduring activity. This is a recorded content from that conference on 03/15/25.  However, you may enroll in this activity to review the contents. 

This recorded webcast, Atlanta Genitourinary Cancers Summit is a multi-format educational experience focused on the latest advances in GU oncology, covering prostate, kidney, bladder, and rare cancers. Available as a live conference on March 15, 2025, a recorded webcast, and an interactive gamified activity, the summit is designed for oncologists, fellows, and other healthcare professionals. Through expert-led sessions, attendees will gain evidence-based insights into emerging treatments, guideline updates, and practical strategies via case-based discussions. The summit emphasizes personalized, patient-centered care, equipping practitioners with enhanced skills to improve outcomes and address disparities in cancer care across different learning formats.

REGISTRATION FEES:

This activity is free for all.

Target Audience

  • Medical Oncologists
  • Surgical Oncologists
  • Radiation Oncologists
  • Oncology Fellows/Residents
  • Oncology Nurses
  • Nurse Practitioners
  • Physician Assistants
  • Oncology Pharmacists

Learning Objectives

Upon successful completion of this educational activity, participants will be able to:

  1. Review current standards and evolving strategies for the management of both localized and advanced genitourinary malignancies.
  2. Incorporate practice-changing clinical data and expert recommendations to optimize clinical outcomes for patients with genitourinary cancers.
  3. Select treatment plans based on patient and disease factors.
  4. Compare and contrast the safety and efficacy profiles of various therapeutic strategies to enhance decision-making in the management of patients with genitourinary cancers

You may also be interested in

2025 Nebraska Congress on Hematologic Malignancies: Recent Advances and Cellular Therapy

The 2025 Nebraska Congress on Hematologic Malignancies: Recent Advances and Cellular Therapy is a one-day CME-accredited, in-person conference that convenes leading experts to discuss the latest advances in the management of benign and malignant hematologic disorders.
Course summary
Available credit: 
  • 6.00 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 6.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 6.00 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 0.00 Attendance
  • 6.00 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 6.00 Contact Hours.
Course opens: 
03/25/2025
Course expires: 
03/25/2026
Cost:
$0.00

Program

This educational activity features recorded videos from the live conference titled Atlanta Genitourinary Cancers Summit held 03/15/25.

The videos are placed in the following order. Feel free to view the content that is relevant to you.

Participants should claim continuing education credits to the extent of their participation.

1 hour and 30 minutes — Session 1: Prostate Cancer

Session Chair: Bradley Carthon, MD

Current Treatment Landscape for mHSPC - Chandler Park, MD

Treatment Updates in mCRPC - Rohan Garje, MD

Case-Based Discussion - Louis Crain Garrot, MD

1 hour and 30 minutes — Session 2: Kidney Cancer

Session Chair: Mehmet Asim Bilen, MD

Evolving Landscape of Treatment for First Line mRCC - Pedro Barata, MD, MSc, FACP

Current and Emerging Treatments in Non-Clear Cell RCC and Subsequent Line Advanced Clear-Cell RCC - Benjamin Maughan, MD, PharmD

Case-Based Discussion - Shahid Ahmed, MD, MBBS; Viraj Master, MD, PhD, FACS

1 hour and 30 minutes — Session 3: Bladder Cancer

Session Chair: Shreyas Joshi, MD, MPH

Guideline Recommended Care in mUC - Rohit Jain, MD

Emerging Treatment Options for MIBC - Arnab Basu, MD, MPH, FACP

Case-Based Discussion - Jacqueline Brown, MD

1 hour and 30 minutes — Session 4: Rare Tumors

Session Chair: Vikram Narayan, MD

03:00 PM – 03:20 PM  Management of Penile Cancer - Viraj Master, MD, PhD, FACS

03:20 PM – 03:40 PM  Novel Treatment Approaches for ACC - Matt Campbell, MD, MS

03:40 PM – 04:30 PM  Case-Based Discussion - Bassel Nazha, MD, MPH; Walid Shaib, MD

 

Faculty

IDENTIFICATION AND MITIGATION OF POTENTIAL CONFLICT OF INTERESTS:

All conflict of interest has been identified and mitigated for individuals in control of contents.

PLANNING COMMITTEE DISCLOSURE STATEMENT:

None of the members of the planning committee, nor any member of their immediate families, have a relevant financial interest in or affiliation with any commercial supporter of this educational activity and/or with the manufacturer(s) of commercial products and/or providers of any commercial services discussed in this educational activity.

 

Course Director(s)

Binay Shah, MD, MHA has no relevant financial relationships to disclose at this time.

 

Conference Chair(s)

Mehmet Bilen, MD has a financial relationship (Other) with Exelixis, Bayer, BMS, Eisai, Pfizer, AstraZeneca, Janssen, Calithera Biosciences, Genomic Health, Nektar, EMD Serono, SeaGen, and Sanofi ; financial relationship (Grant Or Contract) with Merck, Xencor, Bayer, Bristol-Myers Squibb, Genentech/Roche, SeaGen, Incyte, Nektar, AstraZeneca, Tricon Pharmaceuticals, Exelixis, Nikang, Loxo Oncology, Ambrx, Regeneron, Acrivon Therapeutics, Amgen, Genome & Company, AAA, Peloton Therapeutics, Pfizer.

Yousef Zakharia, MD has a financial relationship (Professional Services) with Gilead ; financial relationship (Professional Services) with Seagen ; financial relationship (Professional Services) with Janssen; financial relationship (Professional Services) with Eisai ; financial relationship (Professional Services) with Exelixis.

 

Session Chair(s)

Mehmet Bilen, MD has a financial relationship (Other) with Exelixis, Bayer, BMS, Eisai, Pfizer, AstraZeneca, Janssen, Calithera Biosciences, Genomic Health, Nektar, EMD Serono, SeaGen, and Sanofi ; financial relationship (Grant Or Contract) with Merck, Xencor, Bayer, Bristol-Myers Squibb, Genentech/Roche, SeaGen, Incyte, Nektar, AstraZeneca, Tricon Pharmaceuticals, Exelixis, Nikang, Loxo Oncology, Ambrx, Regeneron, Acrivon Therapeutics, Amgen, Genome & Company, AAA, Peloton Therapeutics, Pfizer.

Bradley Carthon, MD, PhD has no relevant financial relationships to disclose at this time.

Shreyas Joshi has a financial relationship (Professional Services) with Photocure; financial relationship (Professional Services) with Blue Earth Diagnostics; financial relationship (Professional Services) with Engene; financial relationship (Professional Services) with CG Oncology.

Vikram Narayan, MD, FACS has a financial relationship (Grant Or Contract) with Janssen ; financial relationship (Grant Or Contract) with Photocure; financial relationship (Professional Services) with Ferring; financial relationship (Professional Services) with Lily.

Yousef Zakharia, MD has a financial relationship (Professional Services) with Seagen ; financial relationship (Professional Services) with Janssen; financial relationship (Professional Services) with Eisai ; financial relationship (Professional Services) with Exelixis; financial relationship (Professional Services) with Gilead .

 

Speaker/Topic Presenter(s)

Pedro Barata, MD, MSc, FACP has a financial relationship (Professional Services) with Bayer; financial relationship (Professional Services) with Merck; financial relationship (Professional Services) with Eisai; financial relationship (Professional Services) with Pfizer; financial relationship (Professional Services) with BMS; financial relationship (Professional Services) with Ipsen; financial relationship (Professional Services) with AStellas ; financial relationship (Professional Services) with Caris Life Sciences; financial relationship (Professional Services) with Aveo Oncology; financial relationship (Professional Services) with AstraZeneca.

Arnab Basu, MD, MPH has a financial relationship (Independent contractor) with Exelixis; financial relationship (Independent contractor) with EMD Serono; financial relationship (Independent contractor) with Eisai; financial relationship (Independent contractor) with Astellas; financial relationship (Independent contractor) with Arcus.

Matthew Campbell, MD, MS has a financial relationship (Grant Or Contract) with Exelixis; financial relationship (Independent contractor) with SeaGen; financial relationship (Independent contractor) with MJH Life Sciences; financial relationship (Grant Or Contract) with AstraZeneca; financial relationship (Independent contractor) with Pfizer; financial relationship (Independent contractor) with Dava Oncology; financial relationship (Grant Or Contract) with Pfizer; financial relationship (Independent contractor) with Eisai; financial relationship (Independent contractor) with Curio Sciences; financial relationship (Grant Or Contract) with Janssen; financial relationship (Independent contractor) with Exelixis.

rohan garje  has no relevant financial relationships to disclose at this time.

Rohit Jain, MD, MPH has a financial relationship (Independent contractor) with BMS; financial relationship (Independent contractor) with Axiom Healthcare Strategies; financial relationship (Independent contractor) with Eli-Lilly; financial relationship (Grant Or Contract) with Gilead; financial relationship (Independent contractor) with Johnson and Johnson; financial relationship (Grant Or Contract) with BMS.

Viraj Master, MD PhD FACS has a financial relationship (Other) with Exelexis; financial relationship (Other) with Merck; financial relationship (Other) with Telix.

Benjamin Maughan, M.D., PharmD has a financial relationship (Independent contractor) with AVEO Oncology; financial relationship (Independent contractor) with Clovis; financial relationship (Independent contractor) with Bayer Oncology; financial relationship (Independent contractor) with Telix; financial relationship (Independent contractor) with Pfizer; financial relationship (Independent contractor) with Bristol-Myers Squibb; financial relationship (Independent contractor) with Exelixis; financial relationship (Independent contractor) with Sanofi; financial relationship (Independent contractor) with Abbvie; financial relationship (Independent contractor) with Astellas; financial relationship (Independent contractor) with Merck; financial relationship (Independent contractor) with Lilly; financial relationship (Independent contractor) with NCCN; financial relationship (Independent contractor) with Janssen; financial relationship (Independent contractor) with Tempus; financial relationship (Independent contractor) with Peloton Therapeutis; financial relationship (Independent contractor) with Xencor.

Chandler Park, Medical Doctor, Masters in Science has a financial relationship (Grant Or Contract) with Astellas; financial relationship (Grant Or Contract) with Exelexis; financial relationship (Grant Or Contract) with Pfizer; financial relationship (Grant Or Contract) with Bristol Myers Squibb; financial relationship (Grant Or Contract) with Janssen ; financial relationship (Grant Or Contract) with Bayer; financial relationship (Grant Or Contract) with Gilead; financial relationship (Grant Or Contract) with Aveo; financial relationship (Grant Or Contract) with AstraZeneca; financial relationship (Grant Or Contract) with Genentech; financial relationship (Grant Or Contract) with Roche.

 

Case Presenter(s)

Shahid Ahmed has no relevant financial relationships to disclose at this time.

jacqueline brown, Assistant Professor has a financial relationship (Independent contractor) with Xencor; financial relationship (Financial Support) with Medicenna; financial relationship (Financial Support) with Hookipa ; financial relationship (Independent contractor) with Astra Zeneca; financial relationship (Independent contractor) with Pfizer; financial relationship (Financial Support) with Duality Biologics; financial relationship (Independent contractor) with Gilead; financial relationship (Independent contractor) with Exelixis; financial relationship (Financial Support) with Pliant Therapeutics; financial relationship (Independent contractor) with EMD Serono; financial relationship (Financial Support) with Merck Sharpe and Dohme; financial relationship (Financial Support) with Macrogenics.

L Garrot, MD has a financial relationship (Independent contractor) with Eisai.

Bassel Nazha, MD, MPH has a financial relationship (Professional Services) with ntrinsiQ Specialty Solutions; financial relationship (Professional Services) with Exelixis; financial relationship (Professional Services) with Neogenomics; financial relationship (Professional Services) with Intellisphere; financial relationship (Professional Services) with Cardinal Health.

Walid Shaib has a financial relationship (Professional Services) with speaker; financial relationship (Professional Services) with speaker; financial relationship (Professional Services) with speaker.

 

 

Accreditation

Important Information about Claiming CME for this activity:

If you participated in the live course titled Atlanta Genitourinary Cancers Summit on 03/15/25 and claimed CME credits/MOC points for that activity, you do not qualify for CME credits/MOC points for your participation in this enduring activity. This was recorded from the live course on 03/15/25.

 

Available Credit

  • 6.00 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 6.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 6.00 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 0.00 Attendance
  • 6.00 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 6.00 Contact Hours.

Register/Take course

Price

Cost:
$0.00
Please login or register to take this course.

REGISTRATION FEES:

This activity is free for all.